Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.

Katelijne van de Vooren, Silvy Duranti, Alessandro Curto, Livio Garattini
Author Information
  1. Katelijne van de Vooren: CESAV, Centre for Health Economics, IRCCS Institute for Pharmacological Research 'Mario Negri', Via Camozzi, 3 c/o Villa Camozzi, Ranica, 24020, Bergamo, Italy.

Abstract

INTRODUCTION: Diseases caused by Streptococcus pneumoniae (pneumococcus) are a major global public health problem. Despite their importance, information on the burden of the different pneumococcal diseases is limited and estimates vary widely.
OBJECTIVE AND METHODS: We critically reviewed the full economic evaluations (FEEs) on the new pneumococcal conjugate vaccines (PCVs) conducted in the European Union (EU) to assess their potential contribution to public decision making. We selected the FEEs focussed on PCV-10 and PCV-13 and published in English from January 2007 until June 2013. We screened the selected articles to assess their main methodological features using a common checklist composed of epidemiological, clinical and economic items.
RESULTS: All the ten studies selected were based on modelling and the time horizon was always long term. Two studies focused on adults, the remaining eight on infants. Only one study based herd immunity on national data, eight used foreign data or modelling and the last did not consider it. National prices and tariffs were claimed to be sources for unit costs in all studies; however, half of them assumed price parity when one vaccine was not yet marketed, and the figures varied within the countries where more than one study was conducted. Conclusions supported the economic utility of pneumococcal vaccination in all studies, raising some concern only in (i) the independent study, which found that PCV-13 was borderline cost effective, and (ii) the study sponsored by both manufacturers, which estimated an incremental ratio slightly above the national threshold for both PCV-10 and PCV-13.
CONCLUSION: The European studies we analysed are mostly based on weak sources of data. Because of the limited information on vaccine effectiveness and lack of epidemiological and economic data, the need for extensive recourse to assumptions leads to great within- and between-study variability generated by authors' choices.

References

  1. Am J Epidemiol. 1993 May 1;137(9):977-88 [PMID: 8317455]
  2. An Pediatr (Barc). 2004 Feb;60(2):125-32 [PMID: 14757015]
  3. Vaccine. 2010 Nov 19;28 Suppl 6:G14-22 [PMID: 21075265]
  4. Qual Life Res. 2005 Jun;14(5):1311-20 [PMID: 16047506]
  5. Eur J Clin Microbiol Infect Dis. 2007 Aug;26(8):531-40 [PMID: 17570001]
  6. Pediatr Infect Dis J. 2002 Sep;21(9):810-5 [PMID: 12352800]
  7. Vaccine. 2011 Jun 10;29(26):4400-4 [PMID: 21504773]
  8. Clin Ther. 2010 Aug;32(8):1517-32 [PMID: 20728764]
  9. Hum Vaccin Immunother. 2012 Oct;8(10):1382-94 [PMID: 23095867]
  10. MMWR Morb Mortal Wkly Rep. 2008 Feb 15;57(6):144-8 [PMID: 18272956]
  11. J Med Econ. 2012;15(1):61-76 [PMID: 22026590]
  12. Clin Infect Dis. 2000 Jul;31(1):58-64 [PMID: 10913397]
  13. Vaccine. 2010 Nov 19;28 Suppl 6:G23-9 [PMID: 21075266]
  14. J Clin Microbiol. 1989 Jan;27(1):1-5 [PMID: 2913022]
  15. Int J Technol Assess Health Care. 2010 Jul;26(3):330-3 [PMID: 20584363]
  16. PLoS One. 2012;7(7):e39150 [PMID: 22815698]
  17. Brain. 2003 May;126(Pt 5):1015-25 [PMID: 12690042]
  18. Expert Rev Vaccines. 2012 Oct;11(10):1235-47 [PMID: 23170992]
  19. J Med Microbiol. 2005 Apr;54(Pt 4):327-331 [PMID: 15770016]
  20. Vaccine. 2011 Dec 6;29(52):9640-8 [PMID: 22027484]
  21. Pharmacoeconomics. 2012 Mar;30(3):213-7 [PMID: 22233523]
  22. Vaccine. 2012 Nov 26;30(50):7205-13 [PMID: 23084850]
  23. J Clin Epidemiol. 2002 Aug;55(8):791-9 [PMID: 12384194]
  24. Pediatr Infect Dis J. 2000 Mar;19(3):187-95 [PMID: 10749457]
  25. BMJ. 2012 Oct 26;345:e6879 [PMID: 23103369]
  26. Am J Respir Crit Care Med. 2002 Mar 1;165(5):713-7 [PMID: 11874820]
  27. Am J Otolaryngol. 1986 Jan-Feb;7(1):47-54 [PMID: 3953969]
  28. Vaccine. 2007 Feb 9;25(8):1355-67 [PMID: 17208339]
  29. Vaccine. 2009 Dec 30;27 Suppl 6:G27-32 [PMID: 20006136]
  30. J Infect. 2007 Nov;55(5):394-9 [PMID: 17720251]
  31. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007 May-Jun;50(5-6):686-700 [PMID: 17514453]
  32. Euro Surveill. 2008 Aug 28;13(35): [PMID: 18761883]
  33. Vaccine. 2009 Mar 4;27(10):1601-8 [PMID: 19146905]
  34. Clin Microbiol Infect. 2005 Dec;11(12):985-91 [PMID: 16307552]
  35. Pediatrics. 2004 Feb;113(2):283-90 [PMID: 14754939]
  36. Vaccine. 2004 Sep 3;22(25-26):3312-22 [PMID: 15308354]
  37. Clin Infect Dis. 2000 Jan;30(1):157-64 [PMID: 10619745]
  38. Clin Ther. 2012 Jan;34(1):177-89 [PMID: 22284997]
  39. Br J Gen Pract. 2006 Mar;56(524):170-5 [PMID: 16536956]
  40. Pediatrics. 2006 Jun;117(6):1879-86 [PMID: 16740826]
  41. Hum Vaccin Immunother. 2013 Mar;9(3):699-706 [PMID: 23295824]
  42. Eur J Health Econ. 2008 Feb;9(1):7-15 [PMID: 17333089]
  43. N Engl J Med. 2004 Oct 28;351(18):1849-59 [PMID: 15509818]
  44. Rev Panam Salud Publica. 2009 Dec;26(6):518-28 [PMID: 20107706]
  45. Vaccine. 2009 Jun 24;27(31):4136-41 [PMID: 19406190]
  46. J Infect Dis. 2010 Jan 1;201(1):32-41 [PMID: 19947881]
  47. Eur J Pediatr. 2009 Oct;168(10):1251-7 [PMID: 19159954]
  48. PLoS One. 2012;7(7):e39927 [PMID: 22808073]
  49. Pharmacoeconomics. 2008;26(3):191-215 [PMID: 18282015]
  50. Value Health. 2010 Aug;13(5):543-51 [PMID: 20345546]
  51. Arch Otolaryngol Head Neck Surg. 1999 Nov;125(11):1214-8 [PMID: 10555692]
  52. Vaccine. 2004 Oct 22;22(31-32):4203-14 [PMID: 15474710]
  53. Value Health. 2008 Sep-Oct;11(5):898-903 [PMID: 18489504]
  54. Clin Ther. 2013 Feb;35(2):119-34 [PMID: 23312274]
  55. Clin Infect Dis. 2000 Aug;31(2):482-7 [PMID: 10987709]
  56. Arch Pediatr Adolesc Med. 2000 Jan;154(1):43-8 [PMID: 10632249]
  57. Vaccine. 2008 Sep 8;26(38):4947-54 [PMID: 18662735]
  58. Lancet Infect Dis. 2011 Oct;11(10):760-8 [PMID: 21621466]
  59. An Pediatr (Barc). 2005 Aug;63(2):125-30 [PMID: 16045871]
  60. Vaccine. 2011 Nov 28;29(51):9521-8 [PMID: 22008820]
  61. Health Econ Rev. 2012 Mar 30;2(1):4 [PMID: 22828176]
  62. Clin Ther. 1996 Jan-Feb;18(1):160-82 [PMID: 8851461]
  63. Scand J Infect Dis. 2001;33(9):667-72 [PMID: 11669224]
  64. Lancet. 2006 Mar 4;367(9512):740-8 [PMID: 16517274]
  65. Scand J Infect Dis. 2004;36(2):139-43 [PMID: 15061670]
  66. Pediatr Infect Dis J. 2003 Jan;22(1):10-6 [PMID: 12544402]
  67. Scand J Infect Dis. 2008;40(9):721-9 [PMID: 18712627]
  68. Arch Pediatr Adolesc Med. 2007 Dec;161(12):1162-8 [PMID: 18056561]
  69. Health Policy. 2009 Feb;89(2):225-38 [PMID: 18639952]
  70. Emerg Infect Dis. 2010 May;16(5):816-23 [PMID: 20409372]
  71. Pharmacoeconomics. 2005;23(2):113-20 [PMID: 15748086]
  72. Ann Intern Med. 2003 Jun 17;138(12):960-8 [PMID: 12809452]
  73. J Infect. 2007 Sep;55(3):233-9 [PMID: 17599417]
  74. MMWR Morb Mortal Wkly Rep. 2005 Sep 16;54(36):893-7 [PMID: 16163262]
  75. BMJ. 2010 Jun 02;340:c2509 [PMID: 20519267]
  76. Vaccine. 2007 May 4;25(18):3669-78 [PMID: 17360082]
  77. Can J Infect Dis Med Microbiol. 2007 Mar;18(2):121-7 [PMID: 18923713]
  78. Pediatr Infect Dis J. 2006 Jun;25(6):494-501 [PMID: 16732146]
  79. Vaccine. 2012 Jun 6;30(26):3944-50 [PMID: 22504662]
  80. Pharmacoeconomics. 2011 Mar;29(3):199-211 [PMID: 21250759]
  81. N Engl J Med. 2001 Feb 8;344(6):403-9 [PMID: 11172176]
  82. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD000422 [PMID: 23440780]
  83. Vaccine. 2009 Apr 14;27(17):2394-401 [PMID: 19428856]
  84. Clin Ther. 2003 Oct;25(10):2614-30 [PMID: 14667962]
  85. Thorax. 2010 Sep;65(9):770-4 [PMID: 20805169]
  86. Eur J Health Econ. 2009 Feb;10(1):25-38 [PMID: 18379830]
  87. J Infect. 2012 Jan;64(1):54-67 [PMID: 22085813]

MeSH Term

Costs and Cost Analysis
Europe
Humans
Pneumococcal Infections
Pneumococcal Vaccines
Vaccines, Conjugate

Chemicals

10-valent pneumococcal conjugate vaccine
13-valent pneumococcal vaccine
Pneumococcal Vaccines
Vaccines, Conjugate

Word Cloud

Created with Highcharts 10.0.0studiespneumococcaleconomicstudydataEuropeanselectedPCV-13basedonepublicinformationlimitedFEEsnewconductedassessPCV-10epidemiologicalmodellingeightnationalsourcesvaccineeffectivenessINTRODUCTION:DiseasescausedStreptococcus pneumoniaepneumococcusmajorglobalhealthproblemDespiteimportanceburdendifferentdiseasesestimatesvarywidelyOBJECTIVEANDMETHODS:criticallyreviewedfullevaluationsconjugatevaccinesPCVsUnionEUpotentialcontributiondecisionmakingfocussedpublishedEnglishJanuary2007June2013screenedarticlesmainmethodologicalfeaturesusingcommonchecklistcomposedclinicalitemsRESULTS:tentimehorizonalwayslongtermTwofocusedadultsremaininginfantsherdimmunityusedforeignlastconsiderNationalpricestariffsclaimedunitcostshoweverhalfassumedpriceparityyetmarketedfiguresvariedwithincountriesConclusionssupportedutilityvaccinationraisingconcernindependentfoundborderlinecosteffectiveiisponsoredmanufacturersestimatedincrementalratioslightlythresholdCONCLUSION:analysedmostlyweaklackneedextensiverecourseassumptionsleadsgreatwithin-between-studyvariabilitygeneratedauthors'choicesCostvaccines:systematicreview

Similar Articles

Cited By